Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CYP11A1 | P05108 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14376977 | 0.84 | KDM4E (0.32) | CYP19A1KDM4ELMNACYP2C19SMN1; SMN2 | |
| SCHEMBL19705223 | 0.81 | KDM4E (0.48) | CYP19A1CRBNKDM4ELMNACYP2C19 | |
| SCHEMBL13262638 | 0.81 | CRBN (0.40) | CYP19A1CRBNKDM4ELMNACYP2C19 | |
| SCHEMBL14157026 | 0.78 | CRBN (0.36) | CRBNSMN1; SMN2OR51E2 | |
| SCHEMBL3079790 | 0.77 | SMN1; SMN2 (0.46) | CYP19A1KDM4ELMNACYP2C19SMN1; SMN2 | |
| SCHEMBL24399386 | 0.72 | CYP19A1 (0.34) | CYP19A1CRBNKDM4ELMNACYP2C19 | |
| SCHEMBL26248385 | 0.72 | CYP19A1 (0.34) | CYP19A1CRBNKDM4ELMNACYP2C19 | |
| SCHEMBL26339129 | 0.72 | KDM4E (0.44) | CYP19A1CRBNKDM4ELMNACYP2C19 | |
| SCHEMBL26339041 | 0.71 | KDM4E (0.42) | CYP19A1CRBNKDM4ELMNACYP2C19 | |
| SCHEMBL27209711 | 0.71 | SMN1; SMN2 (0.36) | CYP19A1CRBNKDM4ELMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173083-A1 | TETRAHYDROINDOLE DERIVATIVES AS EGFR AND/OR HER2 INHIBTORS USEFUL FOR THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20070129578-A1 | Method for the production of 2,2'-dihydroxybiphenyls | BASF AKTIENGESELLSCHAFT (DE) | 2007-06-07 | — | — | US | disclosed |
| EP-1682473-A1 | METHOD FOR THE PRODUCTION OF 2,2'-DIHYDROXYBIPHENYLS | BASF Aktiengesellschaft (DE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005042454-A1 | METHOD FOR THE PRODUCTION OF 2,2'-DIHYDROXYBIPHENYLS | BASF AKTIENGESELLSCHAFT (DE) | 2005-05-12 | — | — | WO | disclosed |
| US-4058462-A | System for sustained release of phenolic material from porous granules of insoluble polymeric phenolic complexes | GAF CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-3985540-A | Metal complexes of hydroxyquinoline and polymeric porous granules | GAF CORPORATION (US) | 1976-10-12 | — | — | US | disclosed |
| US-3954682-A | GRANULES OR BEADS | GAF CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129578-A1 | Method for the production of 2,2'-dihydroxybiphenyls | HAO2, DAO, DDO | CYP19A1 864/4885CRBN 2363/4885KDM4E 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.